Physician profile
John L Millns
NPI 1902895832
$7,688.18
in general payments reported to CMS, 2019-2025
33 companies · $886 in 2025
The $886 reported for 2025 was more than what 90% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $936 · 2021: $917 · 2022: $1,359 · 2023: $1,290 · 2024: $1,051 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,227.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,915.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $631.58 | 2019-2025 | |
| Ucb, INC. | $554.30 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $546.47 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Janssen Biotech, INC. | $500.97 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $390.51 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $385.54 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $356.74 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $301.60 | 2022-2024 | Vtama |
| Genzyme Corporation | $287.83 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $231.03 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $160.18 | 2019-2024 | Jublia, Cabtreo |
| Janssen Scientific Affairs, LLC | $147.98 | 2019 | |
| Revance Therapeutics, INC. | $141.96 | 2025 | Daxi |
| Almirall LLC | $126.69 | 2019-2024 | Seysara |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.74 | 2020-2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.35 | 2022-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $104.55 | 2025 | |
| Biofrontera INC. | $95.72 | 2021-2022 | |
| Stemline Therapeutics INC. | $93.85 | 2020 | |
| Celgene Corporation | $80.67 | 2019 | |
| Dusa Pharmaceuticals, INC. | $70.42 | 2019 | |
| Incyte Corporation | $57.90 | 2021-2023 | Opzelura |
| Organogenesis INC. | $36.10 | 2021 | |
| Myriad Genetic Laboratories, INC. | $34.59 | 2021 | |
| Pfizer INC. | $34.33 | 2020-2022 | |
| Organon LLC | $31.61 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $28.99 | 2020-2021 | |
| Encore Dermatology INC. | $27.87 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.56 | 2024 | Sotyktu |
| Sandoz INC. | $16.66 | 2019 | |
| Galderma Laboratories, L.P. | $16.06 | 2022 | |
| Epi Health, LLC | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Millns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.